Four non-nucleoside reverse transcriptase (RT) inhibitors, 9-Cl-TIBO [(+)-S-4,5,6,7-tetrahydro-9-chloro-5-methyl-6-(3-methyl-2-butenyl)imidazo(4, 5,1-jk)(1,4)-benzodiazepin-2(1H)-thione)], nevirapine (6,11-dihydro-11-cyclopropyl-4-methyl-dipyrido[2,3-b:2′,3′-e]-[1,4]diazepin-6-one), MSA-300 (N-[cis-2-(2–hydroxy-3-acetyl-6-methoxy-phenyl)-cyclopropyl]-N'-(5-chloropyrid-2-yl)-thiourea) and delavirdine {1-(5-methanesulphonamido-1H-indol-2-yl-carbonyl)-4-[3-(1-methylethylamino)pyridinyl] piperazine} were analysed for the mode of action of their inhibition of human immunodeficiency virus type 1 (HIV-1) RT in three different assays utilizing a 96-well microtitre plate format, with solid-phase conjugated poly(rA) as template. These were: (i) direct RT assay, for determination of IC50 values of RT inhibitors; (ii) RT template/primer binding inhibition (BIC) assay, for measuring the effect of various substances on the RT activity binding to template/primer; (iii) RT protein ELISA, for measuring RT protein binding to template/primer with a monoclonal antibodyreactive against a peptide in the RNase H region. MSA-300 and delavirdine gave the lowest IC50 values, ranging from 0.17 μM to 0.24 μM for MSA-300 and from 0.12 μM to 0.38 μM for delavirdine, whereas higher IC50 values of approximately 20 μM were obtained for 9-Cl-TIBO at all primer concentrations. None of the non-nucleoside substances had inhibiting effects on the binding of template, primer, or template/primer to RT protein. Their inhibition of RT activity was not due to prevention of RT binding to template/primer. TIBO, nevirapine and delavirdine bound to RT reversibly, and they bound more tightly to RT template/primer ternary than to RT template binary complex. MSA-300 showed a comparatively high affinity for the enzyme. The utility of the three assays in relation to screening and analysis of RT inhibitory substances is discussed.
ÅhgrenCBäckbroKBellFWCantrellASClemensMColacinoJMDeeterJBEngelhardtJAHögbergMJaskunasSRJohanssonNGJordanCLKasherJSKinnickMDLindPLopezCMorinJMMuesingJRNoreenRÖbergBPagetCJPalkowitzJAParrishCAPrancPRippyMKRydergårdCSahlbergCSwansonSTernanskyRJUngeTVasileffRTVrangLWestSJZhangH & ZhouXX (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy39:1329–1335.
2.
AwadRJKCorriganGEEkstrandLHDThorstenssonRKällanderCFR & GronowitzJS (1997) Measurement of levels of human immunodeficency virus type 1 reverse transcriptase (RT) and RT activity-blocking antibody in human serum by a new standardized colorimetric assay. Journal of Clinical Microbiology35:1080–1089.
3.
BabaMDe ClercqETanakaHUbasawaMTakashimaHSekiyaKNittaIUmezuKWalkerRTMoriSItoMShigetaS & MiyasakaT (1991) Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Molecular Pharmacology39:805–810.
4.
BalzariniJPerez-PerezMJSan-FelixACamarasaMJBathurstICBarrPJ & De ClercqE (1992) Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3′-spiro-5 “-(4”-amino-1“,2”-oxathiole-2“,2”-dioxide)thymine (TSAO-T). Journal of Biological Chemistry267:11831–11838.
5.
BhikhabhaiRCarlssonTUngeTLövgrenS & StrandbergB (1993) Increased yield of homogeneous HIV-1 reverse transcriptase (p66/p51) using a slow purification approach. Journal of Chromatography639:67–74.
6.
De ClercqE (1995) Antiviral therapy for human immunodeficiency virus infections. Clinical Microbiology Reviews8:200–239.
7.
De ClercqE & BalzariniJ (1995) Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS?Farmaco50:735–747.
8.
DebyserZPauwelsRAndriesKDesmyterJKuklaMJanssenPA & De ClercqE (1991) An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proceedings of the National Academy of Sciences, USA88:1451–1455.
9.
DingJDasKMoereelsHKoymansLAndriesKJanssenPAHughesSH & ArnoldE (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnu-cleoside inhibitors. Nature Structural Biology2:407–415.
10.
DuewekeTJPoppeSMRomeroDLSwaneySMSoAGDowneyKMAlthausIWReusserFBussoMResnickLMayersDLLaneJAristoffPAThomasRC & TarpleyWG (1993) U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy37:1127–1131.
11.
EkstrandDHLAwadJ-KKällanderCFR & GronowitzJS (1996) A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation. Biotechnology and Applied Biochemistry23:95–105.
12.
FanNRankKBEvansDBThomasRCTarpleyWG & SharmaSK (1995) Simultaneous mutations at Tyr-181 and Tyr-188 in HIV-1 reverse transcriptase prevents inhibition of RNA-dependent DNA polymerase activity by the bisheteroarylpiperazine (BHAP) U-90152s. FEBS Letters370:59–62.
13.
GoffSP (1990) Retroviral reverse transcriptase: synthesis, structure, and function. Journal of Acquired Immune Deficiency Syndromes3:817–831.
14.
GoldmanMENunbergJHO'BrienJAQuinteroJCSchleifWAFreundKFGaulSLSaariWSWaiJSHoffmanJMAndersonPSHupeDJEminiEA & SternAM (1991) Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences, USA88:6863–6867.
15.
GronowitzJSLennerstrandJPettersonANeumüllerMJohanssonM & KällanderCFR (1992) Determination of IC50 values and the mechanism of action of HIV-1 RT inhibitors, by the use of carrier bound template-primer, template, or primer, with iodine-125 IUTP as substrate. Antiviral Chemistry and Chemotherapy3:203–213.
16.
HargraveKDProudfootJRGrozingerKGCullenEKapadiaSRPatelURFuchsVUMauldinSCVitousJBehnkeMLKlunderJMPalKSkilesJWMcNeilDWRossJMChowGCSkoogMTWuJCSchmidtGEngelWWEberleinWGSaboeTDCampbellSJRossenthalAS & AdamsJ (1991) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. Journal of Medicinal Chemistry34:2231–2241.
17.
KlunderJMHargraveKDWestMCullenEPalKBehnkeMLKapadiaSRMcNeilDWWuJCChowGC & AdamsJ (1992) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. Journal of Medicinal Chemistry35:1887–1897.
18.
KohlstaedtLAWangJFriedmanJMRicePA & SteitzTA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science256:1783–1790.
19.
KoppEBMigliettaJJShrutkowskiAGShihCKGrobPM & SkoogMT (1991) Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template. Nucleic Acids Research19:3035–3039.
20.
LennerstrandJRyttingASÖrvellCGronowitzJS & KällanderCFR (1996) A method for combined immunoaffinity purification and assay of HIV-1 reverse transcriptase activity useful for crude samples. Analytical Biochemistry235:141–152.
21.
MerluzziVJHargraveKDLabadiaMGrozingerKSkoogMWuJCShihCKEcknerKHattoxSAdamsJRosenthalASFaanesREcknerRJKoupRA & SullivanJL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science250:1411–1413.
22.
PauwelsRAndriesKDesmyterJScholsDKuklaMJBreslinHJRaeymaeckersAVan GelderJWoestenborghsRHeykantsJSchellekensHJanssenMACDe ClercqE & JanssenPAJ (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature343:470–474.
23.
PauwelsRAndriesKDebyserZVan DaelePScholsDStoffelsPDe VreeseKWoestenborghsRVandammeAMJanssenCGAnnéJCauwenberghGDesmyterJHeykantsJJanssenMACDe ClercqE & JanssenPAJ (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences, USA90:1711–1715.
24.
RenJEsnoufRHopkinsARossCJonesYStammersD & StuartD (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure3:915–926.
25.
RomeroDLBussoMTanCKReusserFPalmerJRPoppeSMAristoffPADowneyKMSoAGResnickL & TarpleyWG (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA88:8806–8810.
26.
RomeroDLMorgeRAGeninMJBilesCBussoMResnickLAlthausIWReusserFThomasRC & TarpleyWG (1993) Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3-[(1-methylethyl)amino]-pyridinyl. Journal of Medicinal Chemistry36:1505–1508.
27.
ShaoXEkstrandDHLBhikhabhaiRKällanderCFR & GronowitzJS (1997) A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of their mode of action. Antiviral Chemistry and Chemotherapy8:149–159.
28.
TramontanoE & ChengYC (1992) HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587. Biochemical Pharmacology43:1371–1376.
29.
UngeTAholaHBhikhabhaiRBäckbroKLövgrenSFenyöEMHonigmanAPanetAGronowitzJS & StrandbergB (1990) Expression, purification, and crystallization of the HIV-1 reverse transcriptase (RT). AIDS Research and Human Retroviruses6:1297–1303.
30.
UngeTKnightSBhikhabhaiRLövgrenSDauterZWilsonK & StrandbergB (1994) 2.2 Å resolution structure of the amino-terminal half of HIV-1 reverse transcriptase (fingers and palm subdomains). Structure2:953–961.
31.
WhiteELBuckheitRWJRossLJGermanyJMAndriesKPauwelsRJanssenPAJShannonWM & ChirigosMA (1991) A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Research16:257–266.
32.
WuJCWarrenTCAdamsJProudfootJSkilesJRaghavanPPerryCPotockiIFarinaPR & GrobPM (1991) A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry30:2022–2026.
33.
ZhangHVrangLBäckbroKUngeTNoreenR & ÖbergB (1994) Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138→Arg and Tyr-188→His mutations. Antiviral Research24:43–57.
34.
ZhangHVrangLBäckbroKLindPSahlbergCUngeT & ÖbergB (1995) Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127. Antiviral Research28:331–342.
